BRPI0515885A - derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos - Google Patents

derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos

Info

Publication number
BRPI0515885A
BRPI0515885A BRPI0515885-0A BRPI0515885A BRPI0515885A BR PI0515885 A BRPI0515885 A BR PI0515885A BR PI0515885 A BRPI0515885 A BR PI0515885A BR PI0515885 A BRPI0515885 A BR PI0515885A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical agents
phthalazinone derivatives
derivatives
compounds
Prior art date
Application number
BRPI0515885-0A
Other languages
English (en)
Inventor
Edward Boyd
Frederick Brookfield
Guy Georges
Bernhard Goller
Sabine Huensch
Petra Rueger
Matthias Rueth
Stefan Scheiblich
Christine Schuell
Der Saal Wolfgang Von
Justin Warne
Stefan Weigand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0515885A publication Critical patent/BRPI0515885A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE FTALAZINONA, SUA PREPARAçãO E USO COMO AGENTES FARMACêUTICOS". Os objetivos da presente invenção são os compostos de fórmula I seus sais farmaceuticamente aceitáveis, formas enantioméricas, diastereoisómeros e racematos, a preparação dos compostos acima mencionados, medicamentos contendo-os e sua preparação, bem como o uso dos compostos acima mencionados no controle ou prevenção de tal como câncer.
BRPI0515885-0A 2004-09-24 2005-09-23 derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos BRPI0515885A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04022755 2004-09-24
PCT/EP2005/010311 WO2006032518A1 (en) 2004-09-24 2005-09-23 Novel phthalazinone derivatives, as aurora-a kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515885A true BRPI0515885A (pt) 2008-08-12

Family

ID=34926696

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515885-0A BRPI0515885A (pt) 2004-09-24 2005-09-23 derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos

Country Status (16)

Country Link
US (1) US7226923B2 (pt)
EP (1) EP1794148B1 (pt)
JP (1) JP2008514564A (pt)
KR (1) KR100907202B1 (pt)
CN (1) CN101027290B (pt)
AR (1) AR050948A1 (pt)
AT (1) ATE428708T1 (pt)
AU (1) AU2005287458A1 (pt)
BR (1) BRPI0515885A (pt)
CA (1) CA2580198A1 (pt)
DE (1) DE602005013985D1 (pt)
ES (1) ES2323885T3 (pt)
MX (1) MX2007003104A (pt)
RU (1) RU2397166C2 (pt)
TW (1) TW200624431A (pt)
WO (1) WO2006032518A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084214A (zh) 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
KR101487027B1 (ko) 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101405001A (zh) * 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
CA2645728A1 (en) * 2006-03-20 2007-09-27 Edward Boyd (Deceased) Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2008004088A2 (en) * 2006-07-05 2008-01-10 Centre National De La Recherche Scientifique (C.N.R.S.) Iron-copper co-catalyzed process for carbon-carbon or carbon-heteroatom bonding
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
DE102008000872A1 (de) 2007-04-11 2008-11-13 Basf Se Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (pt) 2011-07-01 2018-04-28
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3438089A1 (en) 2013-12-18 2019-02-06 Monsanto Technology LLC Processes for the diazotization of 2,5-dichloroanilines
WO2016130460A2 (en) * 2015-02-09 2016-08-18 The Johns Hopkins University Phthalazinone pyrazole derivatives for treating retinal degenerative disease
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
RU2674761C2 (ru) * 2016-12-21 2018-12-13 федеральное государственное бюджетное образовательное учреждение высшего образования "Тольяттинский государственный университет" Способ получения анилина и катализатор для него
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CN108250150B (zh) * 2018-03-15 2020-12-29 兰州大学 一种肽嗪酮化合物及其制备方法与应用
CN111039940B (zh) * 2019-12-31 2022-10-21 北京鑫开元医药科技有限公司 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途
CN113773263B (zh) * 2020-06-10 2023-09-19 兰州大学 一种4-胺取代酞嗪酮极光激酶b抑制剂及其制备与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
RU2137762C1 (ru) 1994-02-23 1999-09-20 Пфайзер Инк. 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
KR100459052B1 (ko) 1995-12-18 2005-01-15 서젠, 인크. Aur-1및(또는)aur-2관련질병의진단및치료
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384282A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
WO2001055116A2 (en) 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2274035T3 (es) 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
AU2002331621B2 (en) 2001-08-15 2008-06-05 Icos Corporation 2H-phthalazin-1-ones and methods for use thereof
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
HUP0500200A2 (hu) * 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
DE60332433D1 (de) 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
EP1485381B8 (en) 2002-03-15 2010-05-12 Vertex Pharmaceuticals Incorporated Azolylaminoazine as inhibitors of protein kinases
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

Also Published As

Publication number Publication date
EP1794148B1 (en) 2009-04-15
MX2007003104A (es) 2007-06-07
AU2005287458A1 (en) 2006-03-30
TW200624431A (en) 2006-07-16
CA2580198A1 (en) 2006-03-30
CN101027290A (zh) 2007-08-29
ATE428708T1 (de) 2009-05-15
RU2007115161A (ru) 2008-11-10
KR100907202B1 (ko) 2009-07-10
ES2323885T3 (es) 2009-07-27
RU2397166C2 (ru) 2010-08-20
KR20070046193A (ko) 2007-05-02
DE602005013985D1 (de) 2009-05-28
WO2006032518A1 (en) 2006-03-30
CN101027290B (zh) 2010-05-12
US20060089359A1 (en) 2006-04-27
EP1794148A1 (en) 2007-06-13
JP2008514564A (ja) 2008-05-08
US7226923B2 (en) 2007-06-05
AR050948A1 (es) 2006-12-06

Similar Documents

Publication Publication Date Title
BRPI0519567A2 (pt) heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
SE0401342D0 (sv) Therapeutic compounds
BRPI0608178A2 (pt) derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos
BRPI0508485A (pt) compostos de pentafluorsulfanila, sua fabricação e uso como agentes farmacêuticos
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0315106A (pt) Derivados antimicrobianos de [3.1.0]oxazolidinona bicìclica
BRPI0409951A (pt) derivados de anilina, sua produção e uso como agentes farmacêuticos
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
BRPI0509394A (pt) derivados de diazina, sua manufatura e uso como agentes farmacêuticos
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
WO2005016921A3 (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
BRPI0516754A (pt) usos e derivados de benzoxazina e quinoxalina
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
BRPI0511523A (pt) derivados de tioéter, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
BRPI0516030A (pt) triciclos, sua fabricação e uso como agentes farmacêuticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.